NVSEF - Novartis AG

Other OTC - Other OTC Delayed Price. Currency in USD
89.11
+2.00 (+2.30%)
At close: 11:37AM EDT
Stock chart is not supported by your current browser
Previous Close87.11
Open86.10
Bid0.00 x 0
Ask0.00 x 0
Day's Range86.10 - 89.11
52 Week Range68.65 - 98.00
Volume2,144
Avg. Volume36,966
Market Cap202.824B
Beta (5Y Monthly)0.45
PE Ratio (TTM)16.94
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.08 (3.54%)
Ex-Dividend DateMar. 03, 2020
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG – NVS

    Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that the board of directors of Novartis may have breached its fiduciary duties to shareholders.

  • Canadian company AccessNow wins Novartis Innovation Prize for Assistive Tech
    CNW Group

    Canadian company AccessNow wins Novartis Innovation Prize for Assistive Tech

    Over 150 submissions were received for the Innovation Prize, of which ten were chosen as finalists for the judging panel. DORVAL, QC, June 25, 2020 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to announce today that AccessNow, a platform that crowdsources information on the accessibility of public spaces and venues, has won the Novartis Innovation Prize for Assistive Tech for MS.

  • Novartis in Canada once again named to the list of Best Workplaces™ in Quebec
    CNW Group

    Novartis in Canada once again named to the list of Best Workplaces™ in Quebec

    DORVAL, QC, June 23, 2020 /CNW/ - Novartis in Canada has been named to the list of Best Workplaces in Quebec for the second consecutive year. This distinction follows the company's certification as a nationally ranked Great Place to Work®. This ranking was made possible thanks to the feedback from Quebec-based employees across the Novartis businesses including the Innovative Medicines Division (Pharmaceuticals and Oncology business units), as well as Sandoz Canada.

  • Novartis in Canada initiates Community Strong COVID-19 response program
    CNW Group

    Novartis in Canada initiates Community Strong COVID-19 response program

    United Way Centraide Canada & Food Banks Canada to receive donations through the Novartis Pharmaceuticals Canada Inc. and Sandoz Canada Inc. program Special fund created for organizations supporting COVID-19 ...

  • Amblyotech, A Digital Therapeutics Company, Announces It Has Been Acquired by Novartis
    CNW Group

    Amblyotech, A Digital Therapeutics Company, Announces It Has Been Acquired by Novartis

    PHOENIX, April 20, 2020 /CNW/ -- Amblyotech, a US-based digital therapeutics company, announced that it has completed the sale of all of its outstanding shares to Novartis pursuant to a Share Purchase Agreement entered into between each shareholder of Amblyotech and Novartis. After the acquisition, Novartis intends to pursue the development of Amblyotech's novel digital technology for the treatment of amblyopia, also known as "lazy eye."

  • Novartis recognized as one of the Best Workplaces™ in Canada
    CNW Group

    Novartis recognized as one of the Best Workplaces™ in Canada

    DORVAL, QC, April 15, 2020 /CNW/ - Novartis Pharmaceuticals Canada Inc. is proud to announce that the company has been named to the 2020 list of Best Workplaces™ in Canada. The ranking has been made possible thanks to feedback from Canada-based employees across the Novartis businesses. Associates from the Novartis Innovative Medicines Division (Pharmaceuticals and Oncology business units), as well as Sandoz Canada weighed in, contributing to the prestigious ranking.

  • Business Wire

    ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS

    Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business information to the investing public.

  • Novartis completes certification of initial sites in Ontario for first approved Canadian CAR-T therapy, Kymriah® (tisagenlecleucel)
    CNW Group

    Novartis completes certification of initial sites in Ontario for first approved Canadian CAR-T therapy, Kymriah® (tisagenlecleucel)

    DORVAL, QC, Dec. 12, 2019 /CNW/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that sites in Ontario have been certified in accordance with applicable requirements to treat eligible patients with Kymriah® (tisagenlecleucel), the first chimeric antigen receptor T cell (CAR-T) therapy that received regulatory approval in Canada. Patients with relapsed/refractory (r/r) pediatric and young adult B-cell acute lymphoblastic leukemia (ALL) and adult r/r diffuse large B-cell lymphoma (DLBCL) may be eligible to be treated with Kymriah at one of the initially certified Canadian treatment sites.

  • Novartis establishes strategic alliance with Quebec artificial intelligence institute Mila
    CNW Group

    Novartis establishes strategic alliance with Quebec artificial intelligence institute Mila

    DORVAL, QC, Nov. 20, 2019 /CNW/ - Novartis Pharmaceuticals Canada Inc. announced today a strategic alliance with Mila as the company embraces the next chapter of healthcare innovation with new digital technologies and data science. This alliance with Mila underpins the Novartis commitment to leverage data and artificial intelligence (AI) to transform how medicines are discovered, developed and commercialized.

  • Novartis in Canada named to 2019 Best Workplaces™ in Quebec
    CNW Group

    Novartis in Canada named to 2019 Best Workplaces™ in Quebec

    DORVAL, QC, Nov. 13, 2019 /CNW/ - Novartis Pharmaceuticals Canada Inc. has been named to the 2019 list of Best Workplaces in Quebec. This follows a thorough and independent analysis conducted by Great Place to Work® Institute Canada, which certified Novartis as a Great Place to Work® in July. Employees from the Novartis Innovative Medicines Division (Pharmaceuticals and Oncology business units), as well as Sandoz Canada shared their opinion on what it's like to work for Novartis as well as their relationship to the corporate culture.

  • Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah® (tisagenlecleucel)(i)
    CNW Group

    Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah® (tisagenlecleucel)(i)

    DORVAL, QC, Oct. 9, 2019 /CNW/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that sites in Quebec have been certified in accordance with applicable requirements to treat eligible patients with Kymriah® (tisagenlecleucel), the first chimeric antigen receptor T cell (CAR-T) therapy that received regulatory approval in Canada. Patients with relapsed/refractory (r/r) pediatric and young adult B-cell acute lymphoblastic leukemia (ALL) and adult r/r diffuse large B-cell lymphoma (DLBCL) may be eligible to be treated with Kymriah at one of the initially certified Canadian treatment sites.

  • Targeted melanoma combination therapy Tafinlar® plus Mekinist® now reimbursed in Quebec for adjuvant melanoma patients with BRAF V600 mutation and lymph node involvement(i)
    CNW Group

    Targeted melanoma combination therapy Tafinlar® plus Mekinist® now reimbursed in Quebec for adjuvant melanoma patients with BRAF V600 mutation and lymph node involvement(i)

    Targeted combination treatment aims to prevent cancer recurrence for patients who have undergone surgery First targeted adjuvant therapy for melanoma to be listed on the Régie de l'assurance maladie du ...

  • Novartis commemorates 15th annual Ride for Life™ with 'Rose of Hope'
    CNW Group

    Novartis commemorates 15th annual Ride for Life™ with 'Rose of Hope'

    DORVAL, QC, Aug. 27, 2019 /CNW/ - The 15th annual Novartis Ride for Life™ was celebrated with the planting of a special "Rose of Hope" bush in the gardens of Novartis Canadian headquarters in Dorval. The long-distance cycling event has raised more than $1.2 million for breast cancer research since the first ride in 2005. Each participant in the Ride for Life is responsible for raising their own funds for the event, which this year totaled more than $60,000 to support Quebec Breast Cancer Foundation research programs.